Literature DB >> 7712289

Structures of two classes of MHC molecules elucidated: crucial differences and similarities.

P J Bjorkman1, W P Burmeister.   

Abstract

New structures of MHC molecules have significantly improved our understanding of molecular recognition in cellular immunology. Highlights include the first structure of a class II MHC molecule, complexed with a viral peptide and with a bacterial superantigen. A structure of an MHC-like Fc receptor is expected soon. Interesting comparisons can now be made between the recognition properties of MHC and MHC-like proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7712289     DOI: 10.1016/0959-440x(94)90266-6

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  17 in total

1.  Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.

Authors:  Jing Yang; Qing Yi
Journal:  Am J Blood Res       Date:  2011-06-15

Review 2.  Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.

Authors:  Jing Yang; Qing Yi
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

3.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

4.  Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes.

Authors:  O Rötzschke; K Falk; J Mack; J M Lau; G Jung; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

5.  Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Ying Han; Jianliang Yang; Peng Liu; Xiaohui He; Changgong Zhang; Shengyu Zhou; Liqiang Zhou; Yan Qin; Yongwen Song; Yan Sun; Yuankai Shi
Journal:  Oncologist       Date:  2019-04-05

Review 6.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

7.  Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.

Authors:  Mingjun Zhang; Jianfei Qian; Yongsheng Lan; Yong Lu; Haiyan Li; Bangxing Hong; Yuhuan Zheng; Jin He; Jing Yang; Qing Yi
Journal:  Int J Cancer       Date:  2014-02-07       Impact factor: 7.396

8.  Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.

Authors:  Ming-Zhen Zhao; Yu Sun; Xiao-Feng Jiang; Li Liu; Li Liu; Li-Xin Sun
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 9.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

10.  Correlated evolution of nucleotide substitution rates and allelic variation in Mhc-DRB lineages of primates.

Authors:  László Z Garamszegi; Natasja G de Groot; Ronald E Bontrop
Journal:  BMC Evol Biol       Date:  2009-04-12       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.